Yesim Ozguler1, Gulen Hatemi, Hasan Yazici. 1. Istanbul University, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey.
Abstract
PURPOSE OF REVIEW: There is agreement that the management of Behçet's syndrome has recently improved, especially with the wider use of biologics. The aim of this review is to summarize the current management strategies in Behçet's syndrome. RECENT FINDINGS: There is growing experience with tumor necrosis factor-alpha antagonists in the management of eye gastrointestinal and nervous disease in Behçet's syndrome. Interferon-alpha at lower doses may increase its tolerability. Other biologics such as interleukin 1-blocking agents and tocilizumab were used in a small number of patients and also seem to be effective. SUMMARY: Although experiences with biologics have expanded and looks promising, this is mostly observational or retrospective. There still is a lack of controlled trials with these agents, especially in patients with major organ involvement.
PURPOSE OF REVIEW: There is agreement that the management of Behçet's syndrome has recently improved, especially with the wider use of biologics. The aim of this review is to summarize the current management strategies in Behçet's syndrome. RECENT FINDINGS: There is growing experience with tumor necrosis factor-alpha antagonists in the management of eye gastrointestinal and nervous disease in Behçet's syndrome. Interferon-alpha at lower doses may increase its tolerability. Other biologics such as interleukin 1-blocking agents and tocilizumab were used in a small number of patients and also seem to be effective. SUMMARY: Although experiences with biologics have expanded and looks promising, this is mostly observational or retrospective. There still is a lack of controlled trials with these agents, especially in patients with major organ involvement.